Medical devices developed from research at The University of Queensland have been the subject of a major sales agreement with China.
Adjunct Associate Professor Robert Phillips established the health technology company Uscom to translate a decade of cardiovascular research he conducted while completing his PhD and Masters at UQ.
The Uscom deal with China International Intellectech Corporation (CIIC) announced this week is targeted to generate $65 million Australian in sales from China over the next five years.
Uscom, a publicly listed company, develops and manufactures none-invasive and highly accurate cardiovascular and pulmonary devices and monitors.
“We will now proceed to register and market the new Uscom BP+ central blood pressure monitor and the SpiroSonic series of pulmonary testing devices with CIIC,” Associate Professor Phillips said.
“This agreement is transformational for Uscom and shows the commercial outcomes which can arise from innovative academic research.
“During my UQ studies I spent a lot of time teaching in China and developing relationships and continue to work with a number of Chinese Universities.”
Associate Professor Phillips said the devices produce digital outputs which can be adapted to eHealth and home care applications, a sector that is rapidly gaining focus in China.
The equipment can be used in management of sepsis, critical care monitoring, and in clinical and home care delivered asthma and chronic obstructive pulmonary disease medications.
“UQ has created a world leading medical research and clinical training centre,” Associate Professor Phillips said.
“The relationships and credibility of the University has provided an important platform off which innovative ideas can be transformed into life saving devices and practice changing technologies.
“China provides great partnership opportunities for such ventures with a rapidly growing medical health system and an enthusiasm for novel technologies.”
Media: Brian Mallon, School of Medicine communications manager, email@example.com, +61 (0) 403 621 109.